IV Daratumumab versus Subcutaneous Daratumumab

IV Daratumumab versus Subcutaneous Daratumumab

obr

4 months
115 Views
Share
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
Saad Usmani, MD, Chief, Plasma Cell Disorders Program, Hematologic Malignancies, Levine Cancer Institute/Atrium Health, UNC Chapel Hill School of Medicine, compares intravenous daratumumab versus subcutaneous daratumumab.
Up Next Autoplay
Landscape of Metastatic Hormone-Sensitive Prostate Cancer
Landscape of Metastatic Hormone-Sensitive Prostate Cancer
Category: Kidney Cancer
1,151 Views
obr 4 months
Most Anticipated Trial Results Regarding Biomarkers in RCC
Most Anticipated Trial Results Regarding Biomarkers in RCC
Category: Kidney Cancer
416 Views
obr 4 months
Strategies for Treating RCC in the 2nd Line Setting
Strategies for Treating RCC in the 2nd Line Setting
Category: Kidney Cancer
270 Views
obr 4 months
Perspective on Treating Newly Diagnosed RCC Patients
Perspective on Treating Newly Diagnosed RCC Patients
Category: Kidney Cancer
286 Views
obr 4 months
Studies in Sarcomatoid RCC and Urothelial Cancer
Studies in Sarcomatoid RCC and Urothelial Cancer
Category: Kidney Cancer
220 Views
obr 4 months
PDIGREE Trial in Metastatic Untreated RCC
PDIGREE Trial in Metastatic Untreated RCC
Category: Kidney Cancer
130 Views
obr 4 months
Smoldering MM Presented at ASCO 2019
Smoldering MM Presented at ASCO 2019
Category: Multiple Myeloma
179 Views
obr 4 months
MAIA Study Outcomes
MAIA Study Outcomes
Category: Multiple Myeloma
276 Views
obr 4 months
SOPHIA Trial in HER+ Metastatic Breast Cancer
SOPHIA Trial in HER+ Metastatic Breast Cancer
Category: Acute Lymphoblastic Leukemia
136 Views
obr 4 months